Kendall Capital Management Buys 5,445 Shares of Bausch Health Companies Inc. (NYSE:BHC)

Kendall Capital Management raised its stake in Bausch Health Companies Inc. (NYSE:BHC) by 43.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 17,995 shares of the company’s stock after purchasing an additional 5,445 shares during the period. Kendall Capital Management’s holdings in Bausch Health Companies were worth $145,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. CIBC Asset Management Inc increased its stake in Bausch Health Companies by 0.3% in the third quarter. CIBC Asset Management Inc now owns 374,729 shares of the company’s stock valued at $3,060,000 after purchasing an additional 1,082 shares in the last quarter. Tobam increased its stake in Bausch Health Companies by 10.4% in the fourth quarter. Tobam now owns 15,034 shares of the company’s stock valued at $121,000 after purchasing an additional 1,422 shares in the last quarter. Northwest & Ethical Investments L.P. increased its stake in Bausch Health Companies by 13.0% in the third quarter. Northwest & Ethical Investments L.P. now owns 32,384 shares of the company’s stock valued at $264,000 after purchasing an additional 3,734 shares in the last quarter. Sanders Morris Harris LLC increased its stake in Bausch Health Companies by 16.0% in the fourth quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company’s stock valued at $234,000 after purchasing an additional 4,000 shares in the last quarter. Finally, Principal Securities Inc. increased its stake in Bausch Health Companies by 39.7% in the fourth quarter. Principal Securities Inc. now owns 19,220 shares of the company’s stock valued at $155,000 after purchasing an additional 5,464 shares in the last quarter. 78.65% of the stock is owned by institutional investors.

Bausch Health Companies Price Performance

NYSE:BHC opened at $7.14 on Monday. Bausch Health Companies Inc. has a one year low of $3.96 and a one year high of $11.46. The firm has a 50-day moving average of $7.31 and a 200-day moving average of $7.63. The company has a market cap of $2.63 billion, a PE ratio of -59.45, a PEG ratio of 0.37 and a beta of 0.59.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.44). Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. The firm had revenue of $2.56 billion during the quarter, compared to the consensus estimate of $2.51 billion. On average, equities research analysts expect that Bausch Health Companies Inc. will post 4.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on BHC. Jefferies Financial Group reissued a “hold” rating and set a $8.00 target price (down from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. Royal Bank of Canada decreased their target price on shares of Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating for the company in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, Bausch Health Companies has an average rating of “Hold” and an average target price of $7.42.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.